Comparative Pharmacology
Head-to-head clinical analysis: NORINYL 1 50 21 DAY versus NYLIA 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORINYL 1 50 21 DAY versus NYLIA 7 7 7.
NORINYL 1+50 21-DAY vs NYLIA 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norinyl 1+50 21-Day contains norethindrone (a progestin) and mestranol (an estrogen). Mestranol is converted to ethinyl estradiol, which provides negative feedback on gonadotropin release, inhibiting ovulation. Norethindrone suppresses gonadotropins and alters cervical mucus and endometrial lining to prevent implantation.
Combination of ethinyl estradiol and norethindrone; suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial lining.
One tablet (1 mg norethindrone + 0.05 mg mestranol) orally once daily for 21 days, followed by 7 placebo tablets. Start on day 1 of menstrual cycle or first Sunday after onset.
One tablet orally once daily, with each tablet containing 0.035 mg ethinyl estradiol and sequentially 0.5 mg, 0.75 mg, 1 mg norgestimate for days 1-7, 8-14, 15-21 respectively, followed by 7 placebo days.
None Documented
None Documented
Norethindrone: 5-8 hours; Ethinyl estradiol: 7-15 hours; steady-state reached within 5-7 days
Terminal elimination half-life is 14 hours (range 10–18 hours). In renal impairment (CrCl <30 mL/min), half-life extends to 30–50 hours, necessitating dose adjustment.
Renal (40% as metabolites), fecal (50% as metabolites), <1% unchanged
Renal (70% as unchanged drug, 10% as active metabolite), fecal (15%), biliary (5%)
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive